ConvaTec, a developer of medical technologies, has appointed Ken Berger as the company's new cheif executive officer (CEO).
Berger will join the company from 6 March 2012 after David Johnson will step down from the company.
Previously, Berger served at Thermo Fisher Scientific for the last ten years as senior vice president and group president of the Specialty Diagnostics Group, a $2bn high-value diagnostics business.
ConvaTec chairman Toni Weitzberg said Berger’s track record of building highly profitable businesses, combined with diverse global experience and a history of building strong leadership teams is well suited to take ConvaTec to the next level of performance excellence.
ConvaTec CEO Ken Berger said he is pleased to work with Nordic Capital and Avista Capital Partners as CEO of ConvaTec.
"I look forward to work with the ConvaTec team to realize the incredible potential of this business," Berger said.